
The Lancet Oncology in conversation with
Editors at The Lancet Oncology, in conversation with the journal’s authors, explore their latest research and its impact on people’s health, healthcare, and health policy.
A monthly audio companion to the journal, this podcast covers a broad range of topics, from early-stage breast cancer treatment to mRNA vaccines, the access to essential cancer medicines for children to measuring ovarian toxicity, and more.
Podcasting since 2008 • 206 episodes
The Lancet Oncology in conversation with
Latest Episodes
Ian Tannock on Common Sense Oncology principles for phase 3 randomised clinical trials
Professor Ian Tannock (Princess Margaret Cancer Centre and the University of Toronto, Toronto, Canada) discusses his Policy Review on Common Sense Oncology principles for the design, analysis and reporting of phase 3 randomised clinical trials....
•
18:03

Yannick Romero on the changing landscape of national cancer control plans
Dr Yannick Romero (Union for International Cancer Control) discusses his Policy Review on the changing landscape of the national cancer control plans and his work with the international cancer control partnership.Read the full article:<...
•
24:40

M Saiful Huq and Mostafa Aziz Sumon on the series Cancer Care in South Asian Association for Regional Cooperation (SAARC) Countries
Professor M Saiful Huq (Department of Radiation Oncology, University of Pittsburgh School of Medicine, Pittsburgh, USA) and Dr Mostafa Aziz Sumon (Radiation Oncology, Kurmitola General Hospital, Dhaka, Bangladesh) discuss their Series on Cancer...
•
22:15

Steven Horwitz on valemetostat for relapsed or refractory T-cell lymphoma
Dr Steven Horwitz (Memorial Sloan Kettering Cancer Center, New York, NY, USA) discusses a phase 1 study of valemetostat in relapsed or refractory non-Hodgkin lymphoma and a phase 2 study of valemetostat in relapsed or refractory peripheral T-ce...
•
15:07

Zachary Zumsteg on early phase trial design for novel drug-radiotherapy combination
Dr Zachary Zumsteg (Cedars-Sinai Medical Center, Los Angeles, CA, USA) discusses his Review on the challenges and opportunities for early phase clinical trials of novel drug-radiotherapy combinations.Read the full Article:
•
17:21
